Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens

Vaccine

Volumn 24, Issue 25, 2006, Pages 5277-5293

  Vaughan, Thomas E ^a   Skipp, Paul J ^b   O'Connor, C David ^b   Hudson, Michael J ^a   Vipond, Richard ^a   Elmore, Michael J ^a   Gorringe, Andrew R ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Neisseria lactamica; Neisseria meningitidis; Outer membrane vesicle; Proteomics; Tandem mass spectrometry; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; OUTER MEMBRANE PROTEIN; PEPTIDE; PROTEIN;

ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; DRUG IDENTIFICATION; GENE SEQUENCE; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; HUMANS; MASS SPECTROMETRY; MENINGOCOCCAL VACCINES; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEOMICS;

EID: 33744530000     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.013     Document Type: Article

References (56)

1. HPA web site. Meningococcal Reference Unit, Laboratory confirmed Neisseria meningitidis: England and Wales, by Group; 1989/1990 to 2003/2004. http://www.hpa.org.uk/infections/topics_az/meningo/ data_meni_t03.htm.
2. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F.,., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207 discussion 208-10
3. Cassio de Moraes J., Perkins B.A., Camargo M.C.C., Rossetto Hidalgo N.T., Aparecida Barbosa H., Tavares Sacchi C.,., et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 340 8827 (1992) 1074-1078
4. Bjune G., Høiby E.A., Grønnesby J.K., Arnesen Ø., Fredriksen J.H., Halstensen A.,., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
5. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
6. Morley S.L., and Pollard A.J. Vaccine prevention of meningococcal disease, coming soon?. Vaccine 20 5-6 (2001) 666-687
7. Gold R., Goldschneider I., Lepow M.L., Draper T.F., and Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 137 2 (1978) 112-121
8. Gorringe A.R. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?. Exp Rev Vacc 4 3 (2005) 373-379
9. Hollis D.G., Wiggins G.L., and Weaver R.E. Neisseria lactamicus sp. n., a lactose-fermenting species resembling Neisseria meningitidis. Appl Microbiol 17 18 (1969) 71-78
10. Kim J.J., Mandrell R.E., and Griffiss J. Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes. Infect Immun 57 2 (1989) 602-608
11. Oliver K.J., Reddin K.M., Bracegirdle P., Hudson M.J., Borrow R., Feavers I.M.,., et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 70 7 (2002) 3621-3626
12. Gorringe A., Halliwell D., Matheson M., Reddin K., Finney M., and Hudson M. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine 23 17-18 (2005) 2210-2213
13. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O.,., et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14 2 (1991) 67-79 discussion 79-80
14. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J.,., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14 10 (1996) 1001-1008
15. Norheim G., Aase A., Caugant D.A., Høiby E.A., Fritzsønn E., Tangen T.,., et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23 29 (2005) 3762-3774
16. Vipond C., Wheeler J.X., Jones C., Feavers I.M., and Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectroscopy. Human Vacc 1 2 (2005) 80-84
17. Mukhopadhyay T.K., Halliwell D., O'Dwyer C., Shamlou P.A., Levy M.S., Allison N.,., et al. Rapid characterization of outer-membrane proteins in Neisseria lactamica by SELDI-TOF-MS (surface-enhanced laser desorption ionization-time-of-flight MS) for use in a meningococcal vaccine. Biotechnol Appl Biochem 41 Part 2 (2005) 175-182
18. Wilm M., Shevchenko A., Houthaeve T., Breit S., Schweigerer L., Fotsis T.,., et al. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 379 6564 (1996) 466-469
19. Lasonder E., Ishihama Y., Andersen J.S., Vermunt A.M., Pain A., Sauerwein R.W.,., et al. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 419 6906 (2002) 537-542
20. Schirle M., Heurtier M.A., and Kuster B. Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2 12 (2003) 1297-1305
21. Skipp P., Robinson J., O'Connor C.D., and Clarke I.N. Shotgun proteomic analysis of Chlamydia trachomatis. Proteomics 5 6 (2005) 1558-1573
22. Mackinnon F.G., Gorringe A.R., Funnell S.G., and Robinson A. Intranasal infection of infant mice with Neisseria meningitidis. Microb Pathog 12 6 (1992) 415-420
23. Jolley KA, editor. Full information on strain Y92-1009. The Neisseria PubMLST database. http://pubmlst.org/perl/mlstdbnet/mlstdbnet.pl?page=straininfo&file=pub-nm_isolates.xml&id=4945.
24. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MC, editors. Meningococcal vaccines: methods and protocols, vol. 66 of methods in molecular medicine. Totawa, NJ: Humana Press; 2001. Chapter 7, p. 81-107, ISBN: 0-89603-801-7.
25. Shevchenko A., Wilm M., Vorm O., Jensen O.N., Podtelejnikov A.V., Neubauer G.,., et al. A strategy for identifying gel-separated proteins in sequence databases by MS alone. Biochem Soc Trans 24 3 (1996) 893-896
26. Lander E.S., and Waterman M.S. Genomic mapping by fingerprinting random clones: a mathematical analysis. Genomics 2 3 (1988) 231-239
27. Ewing B., Hillier L., Wendl M.C., and Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8 3 (1998) 175-185
28. Ewing B., and Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8 3 (1998) 186-194
29. Gordon D., Abajian C., and Green P. Consed: a graphical tool for sequence finishing. Genome Res 8 3 (1998) 195-202
30. NCBI ftp site. ftp://ftp.ncbi.nih.gov/genbank/genomes/Bacteria/Neisseria_meningitidis/MC58/.
31. Anon, FormatDB README, http://www.ncbi.nlm.nih.gov/BLAST/ docs/formatdb.html; 2004.
32. Gish W, nrdb, http://blast.wustl.edu/pub/nrdb; 2001.
33. Anon, Commands and Utilities Issue 4, Version 2, X/Open Company Limited, Reading, 1992. ISBN: 1-85912-034-2.
34. Rice P., Longden I., and Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16 6 (2000) 276-277
35. Wang J., and Mu Q. Soap-HT-BLAST: high throughput BLAST based on Web services. Bioinformatics 19 14 (2003) 1863-1864
36. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B.,., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72 7 (2004) 4217-4223
37. Serruto D., Adu-Bobie J., Scarselli M., Veggi D., Pizza M., Rappuoli R.,., et al. Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Mol Microbiol 48 2 (2003) 323-334
38. van Ulsen P., van Alphen L., Hopman C.T., van der Ende A., and Tommassen J. In vivo expression of Neisseria meningitidis proteins homologous to the Haemophilus influenzae Hap and Hia autotransporters. FEMS Immunol Med Microbiol 32 1 (2001) 53-64
39. Sanger Institute web site. http://www.sanger.ac.uk/Projects/[N_lactamica/]; 2005.
40. Tatusov R.L., Fedorova N.D., Jackson J.D., Jacobs A.R., Kiryutin B., Koonin E.V.,., et al. The COG database: an updated version includes eukaryotes. BMC Bioinform 4 1 (2003) 41
41. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Griffiths-Jones S, et al. The Pfam protein families database. Nucleic Acids Res 32 (Database issue) 2004;D138-41.
42. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M.,., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
43. Pizza M, Scarlato V, Rappuoli R, Grandi G, Masignani V. Neisseria meningitidis antigens. Patent number WO9936544-A/87; 1999.
44. Ait-Tahar K., Wooldridge K.G., Turner D.P., Atta M., Todd I., and Ala'Aldeen D.A. Auto-transporter A protein of Neisseria meningitidis: a potent CD4+ T-cell and B-cell stimulating antigen detected by expression cloning. Mol Microbiol 37 5 (2000) 1094-1105
45. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 11 (2003) 1730-1740
46. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Brunelli B.,., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
47. Granoff D.M., Moe G.R., Giuliani M.M., Adu-Bobie J., Santini L., Brunelli B.,., et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 167 11 (2001) 6487-6496
48. Robinson K., Wooldridge K.G., Wells D.B., Hasan A., Todd I., Robins A.,., et al. T-cell stimulating protein A elicits immune responses during meningococcal carriage and human disease. Infect Immun 73 8 (2005) 4684-4693
49. Bernardini G., Renzone G., Comanducci M., Mini R., Arena S., D'Ambrosio C.,., et al. Proteome analysis of Neisseria meningitidis serogroup A. Proteomics 4 10 (2004) 2893-2926
50. Chong P., Yang Y.P., Persaud D., Haer M., Tripet B., Tam E.,., et al. Immunogenicity of synthetic peptides of Haemophilus influenzae type b outer membrane protein P1. Infect Immun 63 10 (1995) 3751-3758
51. Hetherington S.V., Patrick C.C., and Hansen E.J. Outer membrane protein binding sites of complement component 3 during opsonization of Haemophilus influenzae. Infect Immun 61 12 (1993) 5157-5163
52. Snyder L.A., Butcher S.A., and Saunders N.J. Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology 147 Pt 8 (2001) 2321-2332
53. Carson S.D., Stone B., Beucher M., Fu J., and Sparling P.F. Phase variation of the gonococcal siderophore receptor FetA. Mol Microbiol 36 3 (2000) 585-593
54. Toleman M., Aho E., and Virji M. Expression of pathogen-like Opa adhesins in commensal Neisseria: genetic and functional analysis. Cell Microbiol 3 1 (2001) 33-44
55. Lewis L.A., Gipson M., Hartman K., Ownbey T., Vaughn J., and Dyer D.W. Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Mol Microbiol 32 5 (1999) 977-989
56. Carr S., Aebersold R., Baldwin M., Burlingame A., Clauser K., Nesvizhskii A., and Working Group on Publication Guidelines for Peptide and Protein Identification Data. The need for guidelines in publication of peptide and protein identification data. Mol Cell Proteomics 3 6 (2004) 531-533